MedMira Inc. (MIR.V)
CAD 0.1
(0.0%)
CAD 0.1
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.5 Million CAD | 32.09% |
| 2022 | 1.57 Million CAD | -8.29% |
| 2021 | 1.71 Million CAD | -8.36% |
| 2020 | 1.87 Million CAD | 8.9% |
| 2019 | 1.71 Million CAD | -25.29% |
| 2018 | 2.3 Million CAD | -11.87% |
| 2017 | 2.61 Million CAD | -52.5% |
| 2016 | 5.49 Million CAD | 50.56% |
| 2015 | 3.65 Million CAD | -15.92% |
| 2014 | 4.34 Million CAD | 55.34% |
| 2013 | 2.79 Million CAD | 1.5% |
| 2012 | 2.75 Million CAD | 21.19% |
| 2011 | 2.27 Million CAD | -26.02% |
| 2010 | 3.07 Million CAD | -0.38% |
| 2009 | 3.08 Million CAD | -20.2% |
| 2008 | 3.86 Million CAD | -11.55% |
| 2007 | 4.36 Million CAD | -33.99% |
| 2006 | 6.61 Million CAD | 19.63% |
| 2005 | 5.53 Million CAD | 15.77% |
| 2004 | 4.77 Million CAD | 0.9% |
| 2003 | 4.73 Million CAD | -0.88% |
| 2002 | 4.77 Million CAD | -29.0% |
| 2001 | 6.73 Million CAD | 100.53% |
| 2000 | 3.35 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 386.36 Thousand CAD | -42.22% |
| 2024 Q1 | 668.72 Thousand CAD | 35.06% |
| 2024 Q3 | 461.7 Thousand CAD | 18.62% |
| 2023 FY | 2.07 Million CAD | 32.09% |
| 2023 Q3 | 527.49 Thousand CAD | 14.74% |
| 2023 Q4 | 495.12 Thousand CAD | -6.14% |
| 2023 Q2 | 459.74 Thousand CAD | -22.88% |
| 2023 Q1 | 596.15 Thousand CAD | 54.1% |
| 2022 Q2 | 445.2 Thousand CAD | 27.56% |
| 2022 Q1 | 349.02 Thousand CAD | -31.17% |
| 2022 FY | 1.57 Million CAD | -8.29% |
| 2022 Q4 | 386.85 Thousand CAD | -1.44% |
| 2022 Q3 | 392.48 Thousand CAD | -11.84% |
| 2021 Q3 | 233.3 Thousand CAD | -53.01% |
| 2021 Q1 | 478.92 Thousand CAD | 18.93% |
| 2021 Q2 | 496.53 Thousand CAD | 3.68% |
| 2021 Q4 | 507.09 Thousand CAD | 117.36% |
| 2021 FY | 1.71 Million CAD | -8.36% |
| 2020 Q2 | 511.76 Thousand CAD | 44.16% |
| 2020 Q4 | 402.68 Thousand CAD | -33.22% |
| 2020 Q1 | 354.99 Thousand CAD | -9.15% |
| 2020 Q3 | 602.99 Thousand CAD | 17.83% |
| 2020 FY | 1.87 Million CAD | 8.9% |
| 2019 Q1 | 421.71 Thousand CAD | -9.98% |
| 2019 FY | 1.71 Million CAD | -25.29% |
| 2019 Q2 | 477.71 Thousand CAD | 13.28% |
| 2019 Q3 | 429.2 Thousand CAD | -10.15% |
| 2019 Q4 | 390.75 Thousand CAD | -8.96% |
| 2018 FY | 2.3 Million CAD | -11.87% |
| 2018 Q1 | 579.86 Thousand CAD | 20.74% |
| 2018 Q3 | 571.66 Thousand CAD | -16.11% |
| 2018 Q2 | 681.44 Thousand CAD | 17.52% |
| 2018 Q4 | 468.44 Thousand CAD | -18.06% |
| 2017 Q4 | 480.25 Thousand CAD | -35.24% |
| 2017 Q2 | 562.52 Thousand CAD | -31.99% |
| 2017 FY | 2.61 Million CAD | -52.5% |
| 2017 Q1 | 827.08 Thousand CAD | -57.5% |
| 2017 Q3 | 741.6 Thousand CAD | 31.84% |
| 2016 Q1 | 1.29 Million CAD | 136.41% |
| 2016 Q4 | 1.94 Million CAD | 61.54% |
| 2016 Q3 | 1.2 Million CAD | 14.58% |
| 2016 FY | 5.49 Million CAD | 50.56% |
| 2016 Q2 | 1.05 Million CAD | -18.85% |
| 2015 Q1 | 938.92 Thousand CAD | -10.12% |
| 2015 FY | 3.65 Million CAD | -15.92% |
| 2015 Q4 | 548.07 Thousand CAD | -39.39% |
| 2015 Q3 | 904.21 Thousand CAD | -28.27% |
| 2015 Q2 | 1.26 Million CAD | 34.26% |
| 2014 Q1 | 727.38 Thousand CAD | 10.29% |
| 2014 FY | 4.34 Million CAD | 55.34% |
| 2014 Q2 | 1.35 Million CAD | 86.76% |
| 2014 Q3 | 1.21 Million CAD | -10.71% |
| 2014 Q4 | 1.04 Million CAD | -13.88% |
| 2013 Q3 | 781.36 Thousand CAD | 9.34% |
| 2013 Q1 | 640.61 Thousand CAD | -9.4% |
| 2013 FY | 2.79 Million CAD | 1.5% |
| 2013 Q2 | 714.63 Thousand CAD | 11.55% |
| 2013 Q4 | 659.53 Thousand CAD | -15.59% |
| 2012 Q4 | 707.07 Thousand CAD | 4.09% |
| 2012 Q3 | 679.3 Thousand CAD | -45.5% |
| 2012 FY | 2.75 Million CAD | 21.19% |
| 2012 Q1 | 682.75 Thousand CAD | 38.84% |
| 2012 Q2 | 1.24 Million CAD | 82.57% |
| 2011 Q1 | 535.66 Thousand CAD | -31.42% |
| 2011 Q2 | 710.84 Thousand CAD | 32.7% |
| 2011 Q3 | 534.81 Thousand CAD | -24.76% |
| 2011 FY | 2.27 Million CAD | -26.02% |
| 2011 Q4 | 491.74 Thousand CAD | -8.05% |
| 2010 Q1 | 740 Thousand CAD | -10.54% |
| 2010 FY | 3.07 Million CAD | -0.38% |
| 2010 Q2 | 857.03 Thousand CAD | 15.81% |
| 2010 Q3 | 694.16 Thousand CAD | -19.0% |
| 2010 Q4 | 781.12 Thousand CAD | 12.53% |
| 2009 Q4 | 827.14 Thousand CAD | 23.09% |
| 2009 Q2 | 798.56 Thousand CAD | 1.56% |
| 2009 Q1 | 786.32 Thousand CAD | -31.73% |
| 2009 FY | 3.08 Million CAD | -20.2% |
| 2009 Q3 | 672.01 Thousand CAD | -15.85% |
| 2008 FY | 3.86 Million CAD | -11.55% |
| 2008 Q3 | 830.47 Thousand CAD | -8.12% |
| 2008 Q2 | 903.91 Thousand CAD | 12.2% |
| 2008 Q1 | 805.62 Thousand CAD | -10.87% |
| 2008 Q4 | 1.15 Million CAD | 38.68% |
| 2007 Q4 | 903.84 Thousand CAD | 10.65% |
| 2007 Q3 | 816.86 Thousand CAD | -38.24% |
| 2007 Q2 | 1.32 Million CAD | -0.26% |
| 2007 Q1 | 1.32 Million CAD | -34.73% |
| 2007 FY | 4.36 Million CAD | -33.99% |
| 2006 Q2 | 1.33 Million CAD | -9.29% |
| 2006 Q1 | 1.47 Million CAD | -0.66% |
| 2006 Q3 | 1.77 Million CAD | 32.68% |
| 2006 Q4 | 2.03 Million CAD | 14.46% |
| 2006 FY | 6.61 Million CAD | 19.63% |
| 2005 Q4 | 1.48 Million CAD | 15.15% |
| 2005 Q3 | 1.28 Million CAD | -13.02% |
| 2005 Q2 | 1.48 Million CAD | 16.03% |
| 2005 Q1 | 1.27 Million CAD | 27.21% |
| 2005 FY | 5.53 Million CAD | 15.77% |
| 2004 Q2 | 1.23 Million CAD | 2.22% |
| 2004 Q3 | 1.33 Million CAD | 8.49% |
| 2004 Q1 | 1.2 Million CAD | -12.18% |
| 2004 FY | 4.77 Million CAD | 0.9% |
| 2004 Q4 | 1 Million CAD | -24.9% |
| 2003 Q1 | 951.2 Thousand CAD | -42.34% |
| 2003 FY | 4.73 Million CAD | -0.88% |
| 2003 Q2 | 1.04 Million CAD | 10.01% |
| 2003 Q3 | 1.36 Million CAD | 30.61% |
| 2003 Q4 | 1.37 Million CAD | 0.46% |
| 2002 Q3 | 1.08 Million CAD | 25.89% |
| 2002 Q1 | 1.17 Million CAD | 0.0% |
| 2002 Q4 | 1.64 Million CAD | 51.61% |
| 2002 FY | 4.77 Million CAD | -29.0% |
| 2002 Q2 | 864.39 Thousand CAD | -26.55% |
| 2001 FY | 6.73 Million CAD | 100.53% |
| 2000 FY | 3.35 Million CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Arch Biopartners Inc. | 3.22 Million CAD | 53.214% |
| Covalon Technologies Ltd. | 14.36 Million CAD | 89.49% |
| Hemostemix Inc. | 2.15 Million CAD | 30.015% |
| Universal Ibogaine Inc. | 5.81 Million CAD | 74.052% |
| Kane Biotech Inc. | 3.46 Million CAD | 56.462% |
| Marvel Biosciences Corp. | 2.31 Million CAD | 34.909% |
| NervGen Pharma Corp. | 17.77 Million CAD | 91.509% |
| XORTX Therapeutics Inc. | 6.38 Million CAD | 76.349% |